5 Topic Commentaries

The Changing Economics of Retina

• 

  Daniel F. Martin, M.D.

  Ophthalmology (Retina/Vitreoretinal Diseases)

  •

  Cleveland Clinic, Cole Eye Institute

  Both drugs were highly effective regardless of the approach to dosing. There was slightly less vision gain with as-needed treatment. Patients seeking the small extra advantage of monthly treatment need to be mindful of the additional burden, risks, and costs of monthly injections. Since as-needed dosing required 10 fewer eye injections over the course of two years and yielded similar visual results, many patients may choose this option.

  Source
• 

  Glenn C. Yiu, M.D., Ph.D.

  Ophthalmology (Retina/Vitreoretinal Diseases)

  •

  UC Davis Health Eye Center

  Injection of anti-VEGF agents for conditions such as age-related macular degeneration, diabetic retinopathy, and retinal vascular occlusions are invasive, costly and a tremendous burden for patients and providers.

  Source
• 

  Philip J. Rosenfeld, M.D., Ph.D.

  Ophthalmology (Retina/Vitreoretinal Diseases)

  •

  Bascom Palmer Eye Institute, University of Miami Miller School of Medicine

  While many news headlines highlight the cost of medicine, OCT is an example of an innovative technology that makes health care more affordable.

  Source
• 

  Raymond Iezzi, M.D.

  Ophthalmology (Retina/Vitreoretinal Diseases)

  •

  Mayo Clinic

  It’s uncomfortable, it’s expensive and there’s a small risk of infection.

  Source
• 

  Eleonora Lad, M.D., Ph.D.

  Ophthalmology (Retina/Vitreoretinal Diseases)

  •

  Duke Eye Center, Duke University

  This affords us an opportunity as clinicians for cost savings and increased accessibility of treatment to patients worldwide.

  Source